In November 2004, Atrix Laboratories, Inc. merged with QLT Inc. of Canada. Atrix Laboratories, Inc. is an emerging specialty pharmaceutical company focused on advanced drug delivery to improve the effectiveness of existing pharmaceuticals and new chemical entities, particularly proteins, peptides and vaccines. With five patented, drug delivery technologies, the Company is developing a diverse portfolio of products, including proprietary oncology, pain management, growth hormone releasing peptide-1, oral interferon and dermatology products. Atrix also forms strategic alliances with large pharmaceutical and biotechnology companies utilizing its various drug delivery systems. The Company has significant strategic alliances with Pfizer Inc., Sanofi-Synthelabo Inc., MediGene AG, Fujisawa Healthcare, Inc., Elan International Services, Ltd., Geneva Pharmaceuticals, Inc. and CollaGenex Pharmaceuticals, Inc.
